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application site the high intrinsic cytotoxicity of 
non-permeant or poorly permeant anticancer drugs. 
Among several drugs that have been tested to date, 
only two drugs have been identified as candidates for 
electrochemotherapy of cancer patients: bleomycin 
and cisplatin 3.
The transport of bleomycin across the nonper-
meabilized plasma membrane is achieved by carrier 
proteins that internalize it by the endocytotic path-
way, but that transport is limited by the low number 
of carrier proteins. Using electroporation to increase 
membrane permeability provides bleomycin with 
direct access to cytosol and transport to d n a . The 
cytotoxicity of bleomycin is thereby increased by a 
multiple of several thousand 3.
Cisplatin transport through the nonpermeabi-
lized plasma membrane is also normally hampered. 
Only 50% of cisplatin is transported through the 
plasma membrane by passive diffusion; the rest is 
transported by carrier molecules. Electroporation 
of the plasma membrane enables increased flux and 
accumulation of the drug in cells, which results in 
an increase in cisplatin cytotoxicity by a multiple of 
up to 80 4.
The principal mechanism of electrochemo-
therapy is the electroporation of cells in tumours, a 
process that increases drug effectiveness by enabling 
the drug to reach the intracellular targets. Other 
mechanisms of electrochemotherapy—for example, 
prolonged drug entrapment in tumours because of a 
transient induced but reversible reduction of tumour 
blood flow, and a vascular disruption effect—are also 
involved, contributing to the overall effectiveness of 
the treatment 3,5,6.
CLINICAL USES
The first clinical study of electrochemotherapy, 
involving head-and-neck tumour nodules, was pub-
lished in 1991 2; several others followed thereafter 7. 
These clinical studies demonstrated the antitumour 
effectiveness of electrochemotherapy with either 
bleomycin or cisplatin, given intravenously or intra-
tumorally. A response was demonstrated in single 
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Several novel tumour-targeting and drug-delivery 
approaches in cancer treatment are currently under-
going intensive investigation, among them physical 
approaches such as tissue electroporation. Since the 
early 1980s, electroporation has proved to be effec-
tive in facilitating the transport of various molecules 
across the plasma membrane. By using short, intense 
electric pulses, the plasma membrane becomes per-
meable to molecules such as bleomycin and cisplatin 
that are otherwise deprived of membrane transport 
mechanisms. The most appropriate electric pulses are 
those of a duration and amplitude suitable to preserv-
ing the viability of cells, allowing for resealing of the 
cell membrane a few minutes after the application 
of the pulses 1.
Electroporation-based cancer treatment ap-
proaches are currently undergoing intensive in-
vestigation in the field of drug delivery and gene 
therapy. The first biomedical application of this 
method of treating cancer came in the form of elec-
trochemotherapy, which, since its beginnings in 
the late 1980s, has evolved into a clinically verified 
treatment approach for cutaneous and subcutaneous 
tumour nodules 2.
DEFINITION AND MECHANISM OF 
ELECTROCHEMOTHERAPY
Electrochemotherapy is defined as a local treatment 
that, through the application of cell-membrane-
permeabilizing electric pulses, potentiates at the 
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and multiple cutaneous or subcutaneous melanoma 
nodules, in breast and head-and-neck cancer nodules, 
and in Kaposi sarcoma, hypernephroma, chondro-
sarcoma, and basal cell carcinoma 7. Recently, a 
prospective multi-institutional study was conducted 
by a consortium of four cancer centers gathered in 
the European ESOPE (European Standard Operat-
ing Procedures of Electrochemotherapy) project. 
The results confirmed the previous reports that 
electrochemotherapy is effective in the treatment of 
cutaneous and subcutaneous tumour nodules with an 
85% objective response rate (74% complete response 
rate), regardless of tumour histology and of drug 
(bleomycin, cisplatin) or route of administration 
used 8. In addition, standard operating procedures 
for electrochemotherapy were published 9.
Currently, electrochemotherapy is being used 
in approximately 40 cancer centres in Europe and 
the United States. Several hundred patients were 
successfully treated in 2008. Current clinical use 
of electrochemotherapy is focused on palliation of 
progressive disease; however, it can also be used as 
cytoreductive treatment before surgical resection in 
an organ-sparing attempt. It has been used in such a 
setting before a sphincter-sparing resection of anal 
melanoma and in digital chondrosarcoma, rescuing 
the finger from amputation. Because of its vascular 
disruption effect, electrochemotherapy is also ef-
fective in the treatment of bleeding metastases 5. 
Furthermore, it could be used to treat basal cell car-
cinoma of the face with curative intent. Its beneficial 
antitumour effects have been proved, giving better 
cosmetic results than excisional surgery does 10.
CURRENT DEVELOPMENTS
Current developments and future medical applica-
tions of tissue electroporation are numerous. Because 
electrochemotherapy with bleomycin or cisplatin has 
been shown to act synergistically with radiotherapy 
in preclinical studies, use of the technique for the 
radiosensitization of cutaneous tumours can be 
foreseen, predominantly in the palliative treatment 
of progressive disease.
The use of electroporation technology in gene 
therapy—moving various kinds of nucleic acids 
(small interfering r n a , plasmid d n a , oligonucleotides) 
into cells—is called “gene electrotransfer.” This ap-
proach needs further development to achieve better 
results, but its clinical use can be foreseen in the near 
future 11. The first phase i and ii clinical studies are 
ongoing 12.
Further development is focused on the use of 
endoluminal electrodes to treat internal tumours, a 
technological development that could be used for ei-
ther electrochemotherapy or gene electrotransfer 5,7.
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